

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A composition to be buccally administered as a tablet or lozenge, comprising a low dosage lipophilic non-steroidal anti-inflammatory (NSAID) or anti-mycotic drug under an amino acid salt form, wherein the composition ~~can~~ is formulated to be passively diffused into buccal and throat mucous membranes when the composition is totally released, dissolved, coated to the mucous membrane, and then absorbed through mucous.

2. (previously presented) The composition according to claim 1, comprising a substrate that makes possible a slow permucosal diffusion that is uniform and localized to the buccopharyngeal cavity.

3. (previously presented) The composition according to claim 1, wherein at least one anti-inflammatory lipophilic non-steroidal anti-inflammatory drug (NSAID) and/or at least one lipophilic anti-mycotic drug is combined with at least one amino acid.